IL6R and myasthenia gravis: Likewise, satralizumab (ENSPRYNGTM, mAbID 586), an IgG2 antibody against IL6R with prolonged half-life, has been recently approved as a therapeutic option for neuromyelitis optica [81] and there is currently a phase III clinical trial for MG recruiting to evaluate the efficacy, safety and pharmacokinetics/pharmacodynamics in patients with generalized MG (clinicaltrials.gov NCT04963270).